KRW 11120.0
(0.54%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 172.64 Billion KRW | -2.44% |
2022 | 176.96 Billion KRW | 17.63% |
2021 | 150.43 Billion KRW | -3.54% |
2020 | 155.95 Billion KRW | 68.12% |
2019 | 92.76 Billion KRW | 35.94% |
2018 | 68.23 Billion KRW | 154.12% |
2017 | 26.85 Billion KRW | 99.07% |
2016 | 13.48 Billion KRW | -4.61% |
2015 | 14.14 Billion KRW | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q1 | 154.94 Billion KRW | -10.25% |
2024 Q2 | 152.98 Billion KRW | -1.26% |
2023 Q2 | 166.43 Billion KRW | 2.9% |
2023 Q3 | 164.23 Billion KRW | -1.32% |
2023 Q4 | 172.64 Billion KRW | 5.12% |
2023 Q1 | 161.74 Billion KRW | -8.6% |
2023 FY | 172.64 Billion KRW | -2.44% |
2022 Q2 | 160.74 Billion KRW | 2.78% |
2022 FY | 176.96 Billion KRW | 17.63% |
2022 Q4 | 176.96 Billion KRW | 9.83% |
2022 Q3 | 161.13 Billion KRW | 0.24% |
2022 Q1 | 156.39 Billion KRW | 3.96% |
2021 FY | 150.43 Billion KRW | -3.54% |
2021 Q3 | 156.3 Billion KRW | 0.66% |
2021 Q2 | 155.27 Billion KRW | 1.15% |
2021 Q4 | 150.43 Billion KRW | -3.75% |
2021 Q1 | 153.51 Billion KRW | 0.0% |
2020 FY | 155.95 Billion KRW | 68.12% |
2019 FY | 92.76 Billion KRW | 35.94% |
2018 FY | 68.23 Billion KRW | 154.12% |
2017 FY | 26.85 Billion KRW | 99.07% |
2016 FY | 13.48 Billion KRW | -4.61% |
2015 FY | 14.14 Billion KRW | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
HLB Pharmaceutical Co., Ltd | 141.35 Billion KRW | -22.136% |
CMG Pharmaceutical Co., Ltd. | 186.85 Billion KRW | 7.605% |
Celltrion Pharm, Inc. | 641.64 Billion KRW | 73.094% |
Huons Global Co., Ltd. | 1317.96 Billion KRW | 86.901% |
DongKook Pharmaceutical Co., Ltd. | 839.53 Billion KRW | 79.436% |
Enzychem Lifesciences Corporation | 211.54 Billion KRW | 18.39% |
Humedix Co., Ltd. | 219.97 Billion KRW | 21.518% |
Boditech Med Inc. | 227.9 Billion KRW | 24.247% |
FutureChem Co.,Ltd | 72.83 Billion KRW | -137.037% |
Huons Co., Ltd. | 537.28 Billion KRW | 67.868% |
BNC Korea Co., Ltd. | 236.15 Billion KRW | 26.894% |
AptaBio Therapeutics Inc. | 92.51 Billion KRW | -86.601% |